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At a glance:  WHAT IS KNOWN ON THIS SUBJECT: PAVMs are a rare curiosity, often 
associated with hereditary hemorrhagic telangiectasia, and should be treated by embolization 
to prevent strokes, brain abscess and hemorrhage.  WHAT THIS PAPER ADDS: This article 
synthesises material from recent manuscripts that have advanced our understanding of 
PAVM prevalence, hypoxemia compensations, phenotypic modifiers, and the need for 
radiation-limiting management strategies. 
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Abstract 250 words 
 
Within the past decade, pulmonary arteriovenous malformations (PAVMs) have evolved from rare 
curiosities, to not uncommon clinical states, with latest estimates suggesting a prevalence of ~1 in 
2,600.  PAVMs provide anatomic right-to-left shunts, allowing systemic venous blood to bypass gas 
exchange and pulmonary capillary bed processing. Hypoxemia and enhanced ventilatory demands 
result, though both are usually asymptomatic.  Paradoxical emboli lead to strokes and cerebral 
abscesses, and these commonly occur in individuals with previously undiagnosed PAVMs. PAVM 
hemorrhage is rare, but is the main cause of maternal death in pregnancy.  PAVM occlusion by 
embolization is the standard of care to reduce these risks. However, recent data demonstrate that 
currently recommended management protocols can result in levels of radiation exposure that would be 
classified as harmful. Recent publications also provide a better appreciation of the hematologic and 
cardiovascular demands required to maintain arterial oxygen content and oxygen consumption in 
hypoxemic patients; identify patient subgroups at higher risk of complications; and emphasise the 
proportion of radiologically-visible PAVMs too small to treat by embolization.  This review therefore 
additionally outlines medical states that exacerbate the consequences of PAVMs.  Chief amongst 
these is iron deficiency which is commonly present due to concurrent hereditary hemorrhagic 
telangiectasia: iron deficiency impairs hypoxemia compensations by restricting erythropoiesis, and 
increases the risk of ischemic strokes.  Management of periodontal disease, dental interventions, 
pulmonary hypertension, and pregnancy also require specific consideration in the setting of PAVMs. 
The review concludes by discussing to what extent previously recommended protocols may benefit 
from modification or revision.   
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INTRODUCTION: 
 
Pulmonary arteriovenous malformations (PAVMs) are structurally abnormal vessels that provide a 
direct capillary-free communication between the pulmonary and systemic circulations (Figure 1), and 
hence an anatomic ‘right-to-left’ shunt (Figure 2). Gas exchange, filtration, and other processing of 
systemic venous blood is impaired. Surprisingly, the dilated, thin wall structures rarely hemorrhage, 
although this is the most common contributor to the 1% rate of maternal death in pregnancy. 
 
 
PAVMs are substantially more prevalent than suggested by autopsy studies of the 1950s, and now 
barely meet the definition of a rare disease: Population-wide cancer screening programs using thoracic 
computerised tomography (CT) suggest PAVMs sufficiently large for detection by CT affect 1 in 
2,630 (95% confidence intervals 1 in 1,315-1 in 5,555).
1  
  
 
Previous review articles summarise the pathophysiology and management recommendations using 
evidence available in 1998,
2,3
 2006,
4,5
 and 2011-2013.
6-11  
As first proposed 60ys ago,
12
 treatment of 
asymptomatic PAVM patients is recommended to prevent later complications,
 
with embolization now 
the standard of care (Figure 3).   
 
However, the last 12 months have witnessed the publication of many PAVM data manuscripts that 
challenge concepts utilised in current management practice. Most importantly, new data demonstrate 
that currently employed protocols can result in levels of radiation exposure that would be classified as 
harmful:
13 
It therefore seems imperative to reconsider risk-benefit considerations. The remainder of 
this review places the new PAVM evidence base in context for the practising pulmonologist, before 
considering to what extent previously recommended protocols may benefit from modification or 
revision. 
 
ETIOLOGY OF PAVMs 
 
Hereditary hemorrhagic telangiectasia (HHT) 
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The most common cause of PAVMs is hereditary hemorrhagic telangiectasia (HHT), a condition 
discussed in detail in HHT guidelines
5 
and more recent HHT review articles.
14-17 
 Some brief 
comments are appropriate here, due to the HHT-bias of the PAVM evidence base, and impact of HHT 
features on PAVM presentation patterns.  
 
HHT affects ~1 in 5-8,000, is transmitted from parent to child as an autosomal dominant trait, and is 
most commonly caused by mutations in endoglin (HHT1), ACVLI/ALK1 (HHT2) or Smad4 (HTJP) 
Arteriovenous malformations (AVMs) and smaller telangiectatic vessels develop at multiple sites 
including nasal, mucocutaneous, pulmonary, hepatic, gastrointestinal and cerebrovascular beds. HHT 
patients usually present with recurrent nosebleeds, iron deficiency anemia, and/or complications 
attributable to previously silent AVMs.  There is also an increased risk of pulmonary hypertension.  
 
The prevalence of PAVMs differs according to HHT genotype, though screening is recommended 
across all genotypes.
5,6,7,14-17
. One series of 199 HHT patients demonstrated CT-evident PAVMs in 
58% with ENG mutations, compared to 18% with mutations in ACVLI/ALK1 (p<0.001).
18
 
Conversely, pulmonary arterial hypertension, and pulmonary venous hypertension attributed to 
hepatic AVMs and high output states, are more common in HHT2,
19 
but are only clinically significant 
in <5% of HHT patients.
20 
 
 
The diagnosis of HHT can be difficult, and is further influenced by socioeconomic and geographical 
factors.
21 
With enhanced awareness of HHT, the reported proportion of PAVM cases with HHT rose 
from ~70% pre 1998,
2,3
 to 93.6% in one series,
22 
with 59% (121/205) PAVM/HHT patients previously 
unaware they had HHT.
22
  
 
 
Non HHT PAVMs 
In a broad PAVM referral practice, the second most common etiology of single PAVMs appears to be 
sporadic, though this diagnosis should not be considered until HHT has been formally sought in the 
proband and family members.  The respective HHT/PAVM prevalences suggest that the proportion of 
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sporadic PAVMs will rise, as more asymptomatic PAVMs are detected in the general population 
through the increasing use of CT scans in medical practice.   
 
Treatment of cyanotic congenital heart disease by surgical generation of a cavo-pulmonary shunt 
frequently leads to PAVM development in the lung not receiving hepatic venous effluent.
23,24
 Rare 
etiological causes include gestational trophoblastic disease, and arteriovenous fistulae induced by 
trauma. The case report-biased literature (27% of PubMed retrievals for “pulmonary arteriovenous 
malformations” from 2003-2012 were single case reports) suggests other causes that may reflect 
chance associations or alternate diagnoses. 
 
 
 
CLINICAL FEATURES OF PAVMs 
 
Presentation patterns 
Clinical features observed in PAVM patients vary widely, and are summarised in Table 1.   
 
 
Dyspnea and asymptomatic hypoxemia 
Hypoxemia due to right-to-left shunting may be severe, but the most striking clinical finding for this 
patient group is the presence of asymptomatic hypoxemia.
26
  
 
Relatively few patients present because of dyspnea, or describe dyspnea on exertion. Dyspnea was the 
reason for presentation in 51% (25/49) of cases by 1949,
25
 47% (201/427) by 1998
3
, but only 14.6% 
(32/219) of a more recent series.
22 
 In 165 consecutive patients,
 
MRC dyspnea grades did not exceed 3 
(dyspnea after ~1 mile on the flat) unless there was significant co-existing cardiopulmonary 
disease.
27
Significantly hypoxemic patients with SaO2 <85% were able to pursue sporting activities to 
a very high level.
26,28  
Formal cardiopulmonary exercise tests (CPET) of 21 PAVM patients with SaO2 
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80%-96%, demonstrated that Borg scale dyspnea, maximal work-rates and peak oxygen consumption 
(V[dot]O2) did not differ according to hypoxemia severity.
28
 
 
 
 
PAVM patients frequently exhibit orthodeoxia,
27 
attributed to basal predominance of PAVMs. 
Although the cardiac literature might suggest platypnea (dyspnea relieved by lying down) should be 
evident,
29
 in 257 consecutive patients with PAVMs, platypnea was not described by any of the 75 
patients whose SaO2 fell by at least 2% on standing.
27 
 
Only six of 95 patients completing a retrospective questionnaire of flight tolerance reported in-flight 
dyspnea, and there was no difference in sea-level SaO2 between those reporting dyspnea, and those 
who did not.
30
  
 
Most strikingly, 86/98 (87.8%) of consecutive patients reported no improvement in dypsnea/exercise 
capacity after embolization had corrected their hypoxaemia.
26 
Those who did note an improvement 
were more likely to have coexisting concurrent diseases such as airflow obstruction, and/or elevated 
pulmonary artery pressure.
26,27
 CPET studies in five patients where median SaO2 increased from 90% 
pre-embolization to 96% post-embolization (p=0.009), demonstrated no difference in peak work-rate 
or peak V[dot]O2 (medians 119W, 1.69L min
-1
 pre;  113W, 1.72L min
-1 
post-embolization).
28
 Four 
patients reset their peak oxygen pulse (oxygen consumption per heart beat) to values almost identical 
to their pre-embolization values.
28 
 
Hemorrhage 
PAVM hemorrhage leading to haemoptysis or hemothorax can be fatal, but is a relatively rare feature of 
PAVMs.  The two main exceptions are if the patient is pregnant,
31,32
 or if PAVMs are perfused at 
systemic pressures, for example due to pulmonary hypertension, or systemic arterial supply (from 
bronchial or non-bronchial systemic arteries) to PAVM sacs.  Systemic arterial supplies may be 
spontaneous, but more commonly develop following PAVM embolization.
33-36 In patients with 
coexisting HHT, hemoptysis also results from nasopharyngeal and endobronchial telangiectasia. 
 
7 
 
 
 
Chest Pain 
Pleuritic chest pain has been described in up to 10% of PAVM patients.  In our experience, and as 
reported,
25,37 
for untreated PAVMs, chest pain is much more commonly a reason for the diagnostic 
imaging to be performed, rather than attributable to the PAVM itself.
  
 
 
Neurological risks due to compromised capillary bed filtration 
Neurological PAVM-associated risks are common, and remain poorly recognised.  Even in recent 
series, the majority of PAVM- induced ischemic strokes or cerebral abscess occurred in patients who 
had not yet received their diagnosis of PAVMs.
22,38
  The median delay from cerebral event to PAVM 
diagnosis was 2ys.
22
  
 
Cerebral abscess 
A Danish epidemiological study demonstrated cerebral abscess rates of 0.4/100,000/year in the 
general population but 155/100,000/year in HHT/PAVM patients.
38 
Cross sectional rates of 7.8-19.0% 
are reported in different series,
2-11,22   
including 9.05% in 219 consecutive PAVM/HHT patients, 
adjusting for ascertainment bias.
22
 
 
Ischemic strokes 
Cross-sectional studies indicate ischemic stroke
2
 rates of 9-18%,
2-11,22 
and 11.3% adjusting for 
ascertainment bias.
22 
Modelling suggests that by 65ys, at least 25% of untreated PAVM patients will 
have a clinical stroke (symptoms lasting >24hs),
20,22 
while a 1999 imaging study identified cortical or 
subcortical infarcts in 34/67 (51%) patients, at a median age of 41 years.
39 
Ischemic stroke risk was 
reduced following embolization of PAVMs.
22
 
 
Migraine headaches 
Multiple studies demonstrate the risk of migraine in HHT patients is approximately doubled if they 
have pulmonary AVMs,
40-44
 and suggest that migraines improve following PAVM treatment.
40,43
  
Migraine features and precipitants appear indistinguishable to migraines in the general population.
44  
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Myocardial infarctions   
Myocardial infarctions also occur as a result of paradoxical emboli,
45
and may have similar 
risk factors as ischemic strokes.
20
   
 
 
Pregnancy-related deaths 
Pregnancy is a hazardous period for women with PAVMs. Absolute risks were quantified in two 
separate series of 487
31 
and 244
32
 pregnancies.   In one series, 1.0% of pregnancies (95% confidence 
intervals 0.1-1.9) resulted in a major PAVM bleed,
31 
and the
 
maternal death rate was 1.00% (95% CI 
0.13, 1.92%).
31 
There are also enhanced risks of pulmonary emboli, and myocardial infarction with 
normal coronary arteries.
31
 In women experiencing a life-threatening event, prior awareness of the 
PAVM of HHT diagnosis was associated with improved survival (p = 0.041).
31
 
 
Longevity 
PAVM development is usually completed by the end of puberty, but despite the clear risks, cross 
sectional series include large proportions of older patients. In our recent series of 497 consecutive 
patients, a quarter were 60ys or older at presentation,
 
and it was not uncommon for patients describing 
cyanosis in childhood to become grandparents and even great-grandparents in their lifetime.
20
 
 
 
Diagnosis and assessment of PAVMS 
 
Radiological methods: 
Imaging modalities define PAVM number, size, nature, and suitability for embolization.
36,46
  ‘Simple’ 
lesions consist of an aneurysmal venous sac communicating with a dilated feeding artery and draining 
vein (Figure 1A).  Other PAVMs are complex plexiform masses with multiple afferent and efferent 
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vessels. Diffuse PAVMs have been defined as multiple small PAVMs affecting a single segment, or 
every segment of one or more lobes.
35,47
  Distinguishing features of possible “PAVM mimics” such as 
a pulmonary varix or bronchocele are presented elsewhere.
 46
 
 
Although PAVMs may be clearly visible on chest radiographs, many are not, and the chest radiograph 
has been reported as being normal in 10 to 40% of instances where clinically significant PAVMs were 
present.
7 Computed tomography (CT) is generally considered the gold-standard investigation for 
diagnosing PAVMs and demonstrating their size and extent prior to therapy, and will detect lesions 
far below the size for which embolization is feasible.  This modality is preferred to magnetic 
resonance (MR) imaging because of its greater resolution. Elegant CT demonstration of angiographic 
anatomy means that diagnostic angiograms are very rarely required: in our center, they are performed 
at the same session as therapeutic embolization, and limited to the lung where PAVMs are sited.
6,7,46,48 
 
Evaluation of right-to-left shunts 
PAVMs provide an anatomic right-to-left shunt: pulmonary arterial blood passing through PAVMs is 
not exposed to ventilated alveoli. This contrasts to the hepatopulmonary syndrome where shunting is 
considered to arise as a result of perfusion-diffusion defects in dilated microvascular channels.  
 
Gas exchange 
Classically, shunts were measured by arterial PaO2 breathing 100% oxygen.  More commonly, arterial 
PaO2 and/or oxygen saturation (SaO2), are measured on air: each is inversely related to the proportion 
of the cardiac output flowing through the shunt (Figure 4). Other methods such as the multiple inert 
gas technique (MIGET) have not been utilised in large PAVM series. 
 
Technetium perfusion scans 
Perfusion scans using technetium-labelled albumin macroaggregates permit precise shunt 
quantification (Figure 4).  As for 100% oxygen quantifications, this method is no longer in general 
use for diagnosis or follow up of PAVMs. 
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Contrast echocardiography(CE) 
More commonly in PAVM practice, the circulatory transit of microbubbles generated by 
intravenously injected echocontrast material is detected, imaging bubbles arriving in the left heart or 
systemic circulation (Figure 2). Microbubbles of gas behave differently to albumin particles on 
pulmonary capillary transit, because the gas rapidly diffuses into the alveolus down the concentration 
gradient, leading to microbubble shrinkage, then collapse.
7
 With the sensitivity to detect single 
microbubble transits, such studies should detect all anatomic shunts, which is the reason why 
transthoracic CE was recommended by the international HHT guidelines committee as the initial 
PAVM screening test.
5
 
 
However, CE studies are also frequently positive in normal lungs, without any detectable impairment 
of gas exchange.
49,50
 Approximately 8% of the general population exhibit this phenomenon at rest,
 
rising to up to 90% on exercise and in other high cardiac output states.
49-52 
There is interest and debate 
regarding the implications and basis of these findings in the general population. The proportion 
attributable to “alveolar transit” bubbles (bubbles that have passed through the capillaries but not fully 
collapsed)
7
 is not known. 
 
In HHT patients, one study demonstrated positive CEs in 85% of patients with HHT1, and 35% with 
HHT2.
18 
However, in HHT1, a positive CE study only provided a 36.3% positive predictive value for 
a treatable PAVM.
18 
The remainder likely reflect both PAVMs below the limits of CT scan detection, 
and normal physiological responses in a state characterised by high cardiac outputs (compensating for 
anaemia,
53
 hypoxemia,
26-28,,54,55 
hepatic and/or other AVMs
56
).    
 
Careful grading of the number of bubbles visible in the left ventricle can facilitate distinction between 
PAVMs and more normal variation. In a combined Dutch-Italian study, Grade 3 shunts (>100 bubbles 
per frame) had a positive predictive value [PPV] for CT-evident PAVMs of 92.5%, compared to a 
PPV of 13.4% for the lowest positive contrast shunt grade (Grade 1, <30 bubbles per frame).
 57 
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NEW INSIGHTS INTO PAVM PHYSIOLOGY AND CLINICAL CONSEQUENCES 
 
Mechanisms to preserve oxygen delivery to the tissues  
 
During chronic compensation, a graded secondary erythrocytotic (‘polycythemic’) response operates 
to maintain arterial oxygen content (CaO2). CaO2 is determined both by oxygenation and hemoglobin, 
with CaO2 breathing room air approximating to 𝑆𝑎𝑂2 × ℎ𝑒𝑚𝑜𝑔𝑙𝑜𝑏𝑖𝑛 ×
1.34
100
 where hemoglobin is 
expressed in g/dl, and SaO2 as a percentage.
58
 In 165 consecutive PAVM patients with SaO2 varying 
from 78.5-99% (median 95%), there was a hemoglobin rise of 0.82g/dl for every 1% fall in SaO2 
(p<0.0001).
26
  Thus,
 
healthy PAVM patients appeared to preserve CaO2 at just over 18mls/dL on 
air,
26-28
 as reported at altitude.
59
  Self-reported exercise tolerance was worse in patients with lower 
CaO2 (p<0.0001).
26 
After correction of hypoxemia by PAVM embolization, secondary eythrocytotic 
responses were lost, hemoglobin fell, and CaO2 returned to pre-embolization values  within months.
26
 
 
PAVM patients have high cardiac outputs at rest and on exercise.
54,55,60 
On exercise, one study 
demonstrated an excessive increase in total pulmonary blood flow (142% of predicted) in relation to 
the observed oxygen consumption ({Vdot}O2), resulting in higher than predicted tissue oxygen 
delivery on exercise.
54
 Data from two studies suggest that on exercise, hypoxemic patients utilise 
increased stroke volumes,
 
with similar heart rates to controls,
28,54 
and this may be regulated through 
maintenance of the oxygen pulse (oxygen delivered/utilised per heart beat).
28 
Cardiac output and 
stroke volume fall after embolization.
55
  
 
Apparently separately, acute falls in SaO2/CaO2 (for example on standing) appear to be compensated 
by increased heart rate: Orthostatic tachycardia was more pronounced in 257 PAVM patients than 40 
controls without orthodeoxia: The age-adjusted pulse rate was 0.79 min
-1
 higher for every 1% fall in 
SaO2 on standing (p<0.001).
27
 Unlike the postural orthostatic tachycardia syndrome (POTS), for 
PAVM patients, more exuberant postural tachycardias predicted better exercise tolerance.
 27 
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Understanding of these findings, and multiple PAVM case reports,
 61
 may be improved using the 
analogy of a train line delivering oxygen to the tissues:
62 
hypoxemia leads to an increased number of 
train carriages (hemoglobin), and/or cardiac work such that blood hypoxemia does not lead to tissue 
hypoxia. The train line analogy also provides an intuitive understanding of why compensation may be 
less successful for hypoxemic patients who have concurrent cardiac disease, or airways/alveolar 
pathologies, particularly in the setting of iron-restricted erythropoeisis.
62  
 
 
 
Exercise adaptations: 
Studies published earlier this year
26,28
 suggest that PAVM patients who participate in intense sporting 
activity may enhance compensatory mechanisms, facilitating oxygen delivery. A CPET study of 21 
patients suggested the strongest predictors of maximal work-rate were lower body mass index, and 
higher anerobic threshold, both of which reflect better aerobic conditioning.
28 
 Of 117 consecutive 
PAVM patients with normal exercise tolerance, a pre-defined athletic group displayed higher 
hemoglobin for their degree of hypoxemia (resulting in higher CaO2),
26
  mirroring general population 
data that exercise training can stimulate bone marrow erythropoiesis, increasing hemoglobin and red 
cell mass.
63
   
 
One PAVM study
26
 suggests mechanisms may include modified iron handling: the median serum 
ferritin was 38ug/L in athletes (IQR 19-77 ug/L) and non-athletic normals (IQR 16-73 ug/L), but 
serum iron was higher in athletes (median  19.5 [IQR 13-28] mol/l) than  non-athletic normals 
(median 14 [IQR 9-17]mol/l, p=0.01).26  This difference could be predicted if intense physical 
activity enhanced skeletal muscle production of erythroferrone:
64
 Erythroferrone was recently 
identified as an erythroblast-synthesized hormone that suppresses hepcidin production
64
 (and hence 
promotes gastrointestinal iron absorption and mobilisation of iron from stores
65
).  However, the same 
protein appears to be synthesised by skeletal muscle,
66 
providing a plausible mechanism for an 
aerobically advantageous adaptation to exercise.   
13 
 
 
 
 
 
Impaired CO2 clearance 
The impairment of gas exchange by right-to-left shunting through PAVMs also impairs H
+
/CO2 
clearance,
58 
resulting in abnormally high ventilator drives.
28,54,60 
On exercise, PAVM patients increase 
minute ventilation (V[dot]E) more than controls for a given increase in CO2 production 
(V[dot]CO2),
28 
with a steeper
 
V[dot]E/V[dot]CO2 slope in patients with lower SaO2.
28 
It is of some 
surprise that recent
28 
and earlier
54,60 
studies indicate that  the ventilatory stimulus from the combined 
O2 and CO2 shunts not only maintains normocapnia, but appears to cause an overshoot, resulting in 
lower end-tidal PCO2 and venous bicarbonate.
28,54,60 
Following successful embolization, end-tidal 
PCO2, V[dot]E/V[dot]CO2 slopes, and lower ventilatory equivalent for CO2 (EqCO2) at nadir 
normalise.
28  
 
The increased ventilation was not captured as dyspnea by Borg scale testing during CPET.
28 
In a large 
observational series, a small group of individuals did notice that ventilatory patterns they had 
experienced during yoga, swimming, and singing resolved following embolization.
26 
 
 
 
Mechanisms of paradoxical emboli 
 
Ischemic stroke 
The 2011 American Heart Association Stroke Guidelines recommended use of anti-platelets agents 
for secondary prophylaxis of ischemic strokes due to PAVMs.
67
 Recent data highlight that 
HHT/PAVM patients with nosebleeds often tolerate antiplatelet and anticoagulant therapies better 
than expected.
68 
 
In the PAVM population, ischemic strokes are not attributable to conventional vascular risk factors 
such as hypertension, hypercholesterolemia, diabetes, or arrhythmias.
20,22
 It was expected that risks 
would increase with the severity of PAVM-induced shunting. An earlier proposed “3mm rule” for a 
14 
 
 
 
feeding artery luminal diameter of clinical consequence was withdrawn,
69
 though 3mm is still referred 
to as a possible threshold for PAVMs requiring embolization.
9
 
 
Paradoxical embolic events are more common in patients with the higher grade contrast 
echocardiography shunts that are more likely to be associated with visible PAVMs seen on CT.
70 
In 
one study, Grade 3 shunts ([PPV]for CT-evident PAVMs 92.5%
57
) were associated with a 10.4 fold 
increase in stroke/abscess, whereas patients with Grade 1 shunts (PPV for CT-evident PAVMs 
13.4%
57
) had no enhanced risk.
70  
Such findings are reassuring for the members of general and HHT 
populations with low grade intrapulmonary shunts by contrast echocardiography, and no evidence of 
PAVMs on a formal CT scan.
 
 
Once PAVMs are sufficiently large for CT detection, or grade 3 shunts, there is little evidence that 
stroke risk is substantially influenced by further increase in shunt size: A prospective series of 219 
consecutive PAVM cases provided no evidence of  increased stroke risk with PAVM severity judged 
by six different biomarkers,
22
 and only a marginal association with low SaO2 in an extended series of 
497 patients.
20
    The strongest stroke risk factors identified to date are low serum iron
20
  (common due 
to inadequate iron intake for HHT hemorrhagic losses
71
); low pulmonary artery pressure (proposed to 
facilitate the paradoxical embolic process
20,22
); and serum fibrinogen,
20
 the predominant circulating 
plasma protein for platelet adhesion.
72
 Both iron deficiency
73 
 and serum fibrinogen
74
 are emerging as 
risk factors for ischemic stroke in the general population,
 
a third of whom have a patent foramen ovale 
that can also lead to paradoxical emboli at specific times.
67,75 
 
The low hemoglobin caused by iron deficiency has been suggested to contribute to stroke risk through 
impaired oxygen delivery.
73
 However, PAVM-induced ischemic strokes are not global hypoxic 
insults, but conventional, focal infarcts, resulting in partial anterior or posterior circulation 
syndromes.
20
   Iron deficiency is associated with increased blood viscosity,
76
 higher factor VIII
77 
and 
venous thrombemboli (VTE).
77  
Conventional VTE can lead to ischemic strokes following paradoxical 
embolism of a pulmonary embolus,
78 
but this is uncommon in PAVM patients.
20,22 
Given the AHA 
15 
 
 
 
recommended  antiplatelet agents for prevention of ischemic strokes in PAVM patients,
67
 the recently 
rediscovered exuberant platelet aggregation in iron deficiency seems a more plausible mechanistic 
link:
20
  Platelets from iron deficient patients (with and without HHT)
20,79
 demonstrate enhanced ex 
vivo aggregation to 5HT (serotonin),
 
providing potential new therapeutic targets.
20,79 
 
Cerebral abscess 
The organisms most commonly isolated from PAVM-associated cerebral abscesses are anaerobic or 
facultative anaerobic organisms of periodontal origin.
22,80
Risk factors identified for PAVM-associated 
cerebral abscess include male gender,
22
 dental hygiene and interventions;
22
 and, once adjusted for 
male gender, a lower SaO2.
22 
A genetic predisposition is suspected due to the frequent recurrence in 
siblings.  
 
Migraines 
Modified pulmonary metabolism of vasoactive amines is usually proposed as a plausible mechanistic 
link between PAVMs and migraines.  The precipitation of migraines following contrast injection for 
nuclear medicine scans
20 
suggests to the current author, that paradoxical emboli may also contribute to 
migraine pathogenesis. 
 
Impact of concurrent cardiopulmonary disease  
Airflow obstruction emerged as a surprising predictor of dyspnea, and improvement in exercise 
tolerance after embolization.
26
 Suggested reasons why patients with airflow obstruction may be less 
able to compensate for PAVMs included impaired ability to achieve the supranormal ventilation 
required for CO2 clearance.
6
 
 
 
Significant pulmonary hypertension results in enhanced risk of PAVM growth and 
rupture/hemoptysis, greater dyspnea (with attendant greater likelihood of symptomatic improvement 
post embolization),
26 
and reduced risk of paradoxical ischemic stroke.
20,22
 PAVM embolization in the 
presence of severe pulmonary hypertension is more hazardous, can be fatal, and temporary balloon 
occlusion does not predict subsequent rises in pulmonary artery pressure.
81
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Physiological and pathological states associated with higher cardiac outputs also appear to impact on 
symptomatic status (Table 1), and often modify risks of PAVM treatment.  Such states include 
pregnancy and iron deficiency (each discussed above), HHT-related hepatic AVMs
56
 and sepsis. 
Formal data are required, but it is this author’s impression that more athletically-trained individuals 
fare better when they encounter such stresses. 
 
 
Altered barometric pressure 
Theoretical concerns that the reduced barometric pressure and relative immobility associated with 
flying might be detrimental were not substantiated in a retrospective questionnaire-based study of 
3,950 flights in 145 HHT patients including 95 with PAVMs.
30 
Scuba divers with right-to-left shunts, 
including PAVMs, are at increased risk of decompression illness, through paradoxical gas embolism, 
leading to vascular obstruction and resultant tissue ischemia.
7
 
 
 
MANAGEMENT STRATEGIES: 
 
Embolization 
PAVM embolization is recommended for first line treatment of PAVMs amenable to treatment.
10
 
Detailed descriptions of embolization techniques are beyond the scope of this text, and the reader is 
referred to recent manuscripts.
6,7,8,10,34,36,46,48,81  
Amplatzer vascular plugs have rapidly become the 
preferred agent for embolization,
 
compared to coils.
36,48,82,83 
Advantages include the ability to occlude 
large diameter feeding arteries with single plugs (thus reducing procedure time and radiation 
exposure), easier occlusion at the neck of the sac, and occlusion over a shorter length of vessel, 
thereby reducing the likelihood of occluding vessels supplying normal lung.
6,7,48
 
 
Benefits of embolization 
17 
 
 
 
Following successful embolization, assuming feeding arteries remain occluded and the PAVM does 
not recruit a new vascular supply from neighbouring pulmonary and/or systemic arteries,
34,36 
organization and remodelling leads to regression of the PAVM sac, and normalization of diameters of 
former feeding arteries/draining veins (Figure 1).
28
   Multiple series have demonstrated anatomic 
resolution of PAVMs; reduction in right-to-left shunting; and improvement in oxygenation following 
embolization (reviewed
2,3,6-11
).  More recent publications highlight reduction in strokes,
20 
migraines,
40,43
 and reduced hematologic (hemoglobin),
26
 cardiac,
 28,55
 and ventilatory
28
 demands.
 
 
 
Limitations of embolization 
There are technical limitations to embolization feasibility: Feeding arteries with luminal diameters <2-
3 mm diameter are technically untreatable using current catheterization methods.  This may be why 
more proximal occlusions (with attendant risks) have been utilized in some centers. The now obsolete 
‘3mm rule’ means that PAVMs purely supplied by such vessels were not included in many of the 
efficacy series. HHT patients often have multiple PAVMs, only a proportion of which are suitable for 
embolization.  In these cases, improvement in shunting, as opposed to complete obliteration of 
PAVMs, is the most realistic outcome that can be offered.    
 
As detailed elsewhere,
36
 PAVM sac persistence after embolization occurred in up to 25% of cases in 
the pre-Amplatzer plug era. One series with an overall persistence rate of 5%, demonstrated 
recanalization through previously embolized feeding arteries accounted for 91% (48/53) of persistent 
PAVMs.
36
  A separate series indicated recanalization was more likely if coils were used singly, or 
placed >1cm from the PAVM sac,
84
 and there are suggestions in the literature that recanalization rates 
may be higher in childhood.
11 
A recent study demonstrated no recanalization 6-40 months after 
embolization of 28 PAVMs with Amplatzer plugs and coils.
82 
 
PAVM sacs that persist after embolization may acquire new pulmonary, and more hazardously 
systemic arterial feeders.
34,36 
This
 
mirrors
 
findings reported for spontanous pulmonary embolic 
occlusions  of normal pulmonary arteries.
85
 The neovascular supplies are less amenable to subsequent 
18 
 
 
 
re-embolization, than recanalized feeding arteries.
36 
  With appropriate evaluations of systemic 
arteries, the development of a systemic arterial supply appears to be frequent (13/32 in
 34
).  
 
 
Risks 
Risks appear to be low in experienced hands where long-term follow up of patients is employed but 
are not zero. Generally, the most common complication of embolization is transient pleurisy which is 
reported in approximately 10% of patients, and can occur in the absence of pulmonary infarction. 
Rates appear higher with peripheral, or diffuse PAVMs.
35
 Paradoxical embolism of devices, thrombi, 
or air bubbles (leading to angina, strokes, or need for retrieval) are rare, and seem to have been 
reduced by technical advances reported in later series. Potential massive hemoptysis from systemic 
arterial collaterals that develop in the months following embolization remains a concern, requiring 
dual systemic (bronchial) and pulmonary angiographic approaches for embolization.
7,9,36 
   
 
 
Specific considerations apply in the setting of pre-existing pulmonary hypertension when occlusion of 
PAVMs can result in acute and fatal increases in PAP. A detailed discussion using data available in 
2008 was presented in
 86
 Our current interpretation of the evidence base is that severe pulmonary 
hypertension remains a relative, if not absolute contraindication to elective embolization.  However, 
further data are needed, particularly since patients with higher PAP are more likely to report a 
symptomatic benefit if PAVMs can be safely occluded.
26
   
 
 
 
Radiation limitation strategies 
In the last few months, the management strategies recommended in Figure 3 have been shown to 
result in harmful radiation burdens over an 11 year period.
13
 In a single center study of 246 PAVM 
patients (mean age, 53 years), the mean cumulative effective dose (CED) over an 11 year period was 
51.7mSv, and CED exceeded 100mSv in 26 patients (11%).
13
 CT scans accounted for 46% of the 
19 
 
 
 
CED, compared to 51% from interventional procedures.
13
 A survey with predominantly North 
American respondents had reported an excess of breast cancer (but no other cancer) in patients with 
HHT.
87 It therefore seems imperative to reconsider radiation exposure at multiple time points, 
particularly in younger patients: 
 
Initial PAVM diagnostic investigations 
In the HHT Community, there have been major efforts to limit radiation exposure at the point of 
screening of HHT family members, with contrast echocardiography recommended.
5 
If genuinely 
negative or Grade 1, this can spare individuals with no evidence of shunting from a single thoracic CT 
scan.   
 
More widely, initial diagnoses often rely on a single thoracic CT scan which in our view is entirely 
reasonable given the risks associated with PAVMs. However, the initial CT may then be followed by 
repeat CT scans, and even diagnostic angiography before referral for formal embolization 
assessments. ‘Stop and refer after first CT’ seems an appropriate simple paradigm that could be 
employed.   
 
There seems some confusion about the likelihood of development of PAVMs in an HHT patient with 
a previously negative CT.  In our experience, carefully performed CT scans, if negative, are unlikely 
to require repeating in adulthood unless clinical circumstances change substantially, thus alternate 
methods of patient evaluation can be utilised (see below). 
 
 
Angiographic treatments 
Treatment-associated exposures are incorporated in risk-benefit considerations. Careful consideration 
is given to whether additional embolization treatment of multiple small (<2mm) feeding vessels is 
likely to carry overall treatment benefit for patients. Where patients appear to be at high risk of 
complications, for example experiencing recurrent ischemic strokes, surgical resection is considered.
 
20 
 
 
 
6,7 
Since children are at higher risk from ionising radiation, where possible we avoid CT scans and 
angiography altogether until after puberty.
6,7,20,22
 
 
Follow up:  
Current international guidelines
 
recommend post-embolization CT scans at 6-12 months, then 
subsequently 3 yearly, with 1-5 yearly CT scans for other patients with CT-evident PAVMs or 
positive contrast echocardiographic studies.
5
 These recommendations were not adopted universally 
due to radiation concerns,
6,7,20,22,88,89 
and in the light of 
13
,
 
are likely to be revised in the future. 
Alternate follow up strategies employed include magnetic resonance imaging, noting resolution is 
currently limiting,
88,89 
exercise testing,
90 
and SaO2 plus chest x-ray (Figure 1; further images in
26
). At 
our institution, CT scans are reserved for patients demonstrating new symptoms, deteriorating SaO2, 
or failure to obliterate a PAVM sac which would have been predicted based on angiographic 
appearances.
6,7
   
 
 
 
Medical management of patients with PAVMs 
As an adjunct to embolization treatments, a number of relatively simple lifestyle and medical 
management recommendations may be employed: 
 
Oxygen for hypoxemic patients:  
Supplementary oxygen can be prescribed for symptomatic patients, but it is important to recognise 
that there is no rationale for prophylactic use to prevent hypoxic pulmonary hypertension, as there is 
no alveolar hypoxia.
26,28,30
   
 
Venesection for polycythemia:  
Secondary polycythemia is an adaptive response. Venesection is not without risk, particularly the 
induction of iron deficiency
76,91 
which will increase cardiac demands to maintain tissue oxygen 
21 
 
 
 
delivery, and is a strong risk factor for paradoxical embolic stroke in PAVM patients.
20
 The pathology 
most resembling PAVMs is cyanotic congenital heart disease, for which UK polycythemia 
guidelines
91
 only recommend venesection if the patient describes symptoms of hyperviscosity 
 
Lung transplantation: 
This has been performed for PAVM patients, but is rarely indicated because of the life expectancy of 
even severely hypoxemic patients. The three patients in our practice
20
 who were referred for lung 
transplantation assessment in the late 1980s/early 1990s (and elected not to proceed) remain stable 20, 
22, and 25 years later. A separate retrospective study of 36 patients with diffuse PAVMs followed up 
8.5ys (0.12-26) years later indicated 24 were working or studying full time, but in one, an attempted 
lung transplant resulted in an operative death.
35 
 
Pregnancy  
To date, it has not been possible to identify women at higher risk of pregnancy-related 
complications.
31 
Unfortunately, maternal deaths and life-threatening pulmonary hemorrhage do occur 
in previously treated patients.
31 
Anglo-French management strategies emphasise the need to inform 
women of the 1% rate of maternal death pre pregnancy and to manage as high risk pregnancies.
31
  
Further specific management details are beyond the scope of this text (see 
31,32
) 
 
 
Dental 
Links between oral bacteria, dental procedures and PAVM-associated cerebral abscess have been 
recognised for many years and were the reason why antibiotic prophylaxis was recommended for 
dental and surgical procedures.  This was originally based on the endocarditis paradigm, noting the 
absolute risk for PAVM patients is several orders of magnitude higher, and mechanisms are likely to 
differ.
92
 Antibiotic prophylaxis is still recommended for patients with PAVMs.
92
  Judicious dental 
hygiene is also recommended.
92
 
 
Iron deficiency    
22 
 
 
 
Optimisation of iron status is emerging as a core principle for management of patients with PAVMs, 
particularly those with HHT and substantial iron losses from nosebleeds,
71
 when conventional iron-
rich diets
 
are insufficient to meet the enhanced iron demands. Iron deficiency restricts hemoglobin 
synthesis/erythrocytosis, and this is an even greater problem for patients with hypoxemia requiring 
supranormal hemoglobins to maintain CaO2,
26
 and/or needing to achieve enhanced cardiac 
outputs.
28,55,56,60
  Iron deficiency is also associated with enhanced risks of venous
77 
and arterial
20
 
thromboses in the HHT/PAVM population.
 
 
 
 
Conclusions  
New data offer opportunities for a balanced, informed approach to PAVM risk management. An 
‘advise and embolize’ approach is recommended, weighing up both benefits and risks of specific 
treatments on an individual basis (Figure 4), before determining a mutually agreed management plan 
with the patient. Using this approach in our practice, embolization is almost always recommended, 
together with adjunct medical measures, and radiation-limiting follow-up strategies. Comparative 
outcome/exposure data, and formal updated management guidance, are urgently required. The terms 
hypoxemia/hypoxia should not be used interchangeably, as commonly observed in publications and 
clinical practice.  
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Table 1: Major physiologic and clinical features of PAVMs 
 
Right-to-left shunting reduce Physiologic compensations increase Clinical features* 
PaO2, SaO2, and CaO2  Hemoglobin (secondary erythrocytosis)
 
 Cyanosis. Often asymptomatic.  
Cardiac output (stroke volume; heart rate) Dyspnea, palpitations, cardiac failure 
CO2 clearance Ventilation (V[dot]E/V[dot]CO2 slope) Different ventilation patterns† 
Capillary filtration/processing Not known Paradoxical embolic stroke, MI 
 
 
Cerebral and/or peripheral abscesses 
Migraine 
  
Clubbing 
Fragile PAVM walls Not known Hemoptysis; hemothorax 
Endothelial cell changes Not known Speculative 
 
Table highlights primary physiology, identified compensatory mechanisms, and resultant clinical features (references in text). *Vascular bruits may be 
audible. †Often not appreciated until post embolization.  SaO2, % oxygen saturation of haemoglobin; CaO2, arterial oxygen content. MI, myocardial 
infarction, 
 
  
 
FIGURE LEGENDS 
 
Figure 1:A) Chest x-ray indicating a PAVM (solid line arrow) and the subtle appearances of associated 
artery and vein (dashed line arrows) in a patient with resting SaO2 94%. B) Thoracic CT scan images. C) 
Angiographic appearances pre (left) and post (right) embolization. Images courtesy of Dr James Jackson, 
were taken minutes apart.  Note that preferential blood flow through the PAVM led to reduced perfusion of 
non-PAVM associated arteries, and dilatation/early filling of the draining vein. Following embolization (with 
two Amplatzer plugs (arrowed)), arterial blood flow to normal pulmonary arteries was restored. D) Chest 
radiographs of the same region 8 months post embolization, when the SaO2  was 97%. Note regression of 
PAVMs sac, feeding artery and draining vein.  The tips and bodies of the Amplatzer plugs are visible.  
 
 
Figure 2: Cartoon indicating the major functions of the pulmonary capillary bed that are bypassed in the 
setting of PAVMs (red arrows) Adapted from reference
20
 with author permission. 
 
Figure 3 Typical 2013 flow chart: Adapted from  reference 8: * indicated to be at rest and on exercise
8
; 
medical management to include use of supplemental oxygen when needed, prophylactic antibiotics 
(including for group with possible microscopic PAVMs) and avoidance of SCUBA diving.  Dotted arrow: as 
indicated in international guidelines, reference 5.  
 
Figure  4: Inverse relationship between right-to-left shunt fraction and oxygen saturation. 309 paired 
same-day values of right-left shunt (quantified by nuclear medicine perfusion scans using Tc-labelled 
albumin macroaggregates), and the mean SaO2 after 7, 8, 9 and 10 minutes standing. Data are from 198 
individuals. Regression coefficient -1.22 (95% CI -1.31, -1.14; p<0.0001). Adapted from
20 
with author 
permission. Note all would be predicted to have Grade 3 shunts by contrast echocardiography. 
 
  
 
Figure 5: 2014 Proposed management flowchart: Irrespective of why PAVMs identified, all should be 
considered for embolization if technically feasible, and suitable expertise available. *Caution required if pre-
existing severe pulmonary hypertension when risk benefit considerations change (increased risk of 
procedural related mortality; reduced benefit form prevention of paradoxical embolic strokes
90
) 
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